Clinical trials: Relapsed AML
Lymphoma
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00898612
- Where
- United States
- Sponsor
- Mayo Clinic
Leukemia
Tipifarnib in Treating Young Patients With Refractory Leukemia
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients who have refractory…
- Trial name
- NCT00022451
- Testing
- tipifarnib
- Where
- 61 sites in United States, Australia and 1 more
- Sponsor
- National Institutes of Health Clinical Center (CC)
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
This is a Phase I study designed to determine the MTD and assess the toxicity associated with clofarabine followed by fractionated cyclophosphamide in patients > 1 year of age or < 21 years of age with relapsed or refractory…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia
- Trial name
- POE07-01 (NCT00852709)
- Testing
- Clofarabine, Cyclophosphamide
- Where
- 7 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients Who Have Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating patients who have hematologic…
- Trial name
- NCT00004047
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo
Leukemia, Myelodysplastic Syndromes
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or…
- Trial name
- NCT00028899
- Testing
- asparaginase, cytarabine, gemtuzumab ozogamicin
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 47 people
- Sponsor
- Children's Oncology Group
Cancer, Pediatric Solid Tumor
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
PARC is an international phase I/II trial evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade…
- Conditions
- Cancer, Pediatric Solid Tumor, Pediatric AML, Pediatric ALL
- Trial name
- PARC (NCT03455140)
- Testing
- PEG- BCT-100
- Where
- 14 sites in Australia, Netherlands and 1 more
- Volunteers
- 49 people
- Sponsor
- University of Birmingham
Childhood Langerhans Cell Histiocytosis, Leukemia
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00008164
- Testing
- umbilical cord blood transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T…
- Trial name
- NCT03126864
- Testing
- Leukapheresis, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
The relapse of acute leukemia, MDS and blast phase CML after allogeneic transplantation affects approximately 1/3 to 1/2 of all transplant recipients and is the main cause of treatment failure.
- Trial name
- NCT00548847
- Testing
- GM-CSF, Interferon-α-2b
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
Acute Myeloid Leukemia
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.
- Trial name
- NCT02027064
- Testing
- Interferon-alpha
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Two key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and pharmacological immunosuppression with insufficient efficacy of…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia, Relapse
- Trial name
- NCT07366801
- Testing
- Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®)
- Where
- Russia
- Volunteers
- 64 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hematologic Malignancy, AML
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN
- Trial name
- NCT05476770
- Testing
- Tagraxofusp, Fludarabine, Cytarabine
- Where
- 31 sites in United States, Australia
- Volunteers
- 54 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Pediatric Acute Myeloblastic Leukemia, Relapsed, Pediatric Acute Lymphoblastic Leukemia, Relapsed
AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
This study is for patients 2-21 years old who have acute leukemia that has not responded well to chemotherapy and will have a bone marrow transplant. This is a pilot (phase 1) study of AMD3100(also called Plerixafor, Mozobil).
- Trial name
- BMTAMD3100 (NCT01655875)
- Testing
- AMD3100
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
- Trial name
- RESOLVE (NCT02203903)
- Testing
- Tumor associated antigen lymphocytes (TAA-T)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Catherine Bollard
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Allogeneic transplant can sometimes be an effective treatment for leukemia. In a traditional allogeneic transplant, patients receive very high doses of chemotherapy and/or radiation therapy, followed by an infusion of their…
- Trial name
- NCT02433483
- Testing
- Cytarabine, Intrathecal Triples, HPC-A
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia
Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating children who have relapsed or…
- Trial name
- NCT00006462
- Testing
- gemcitabine hydrochloride
- Where
- 225 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Children's Oncology Group
Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of BMS-214662 in treating patients who have acute leukemia, myelodysplastic…
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes
- Trial name
- NCT00006213
- Testing
- BMS-214662, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Relapse Leukemia
Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only treatment that offers a possible cure for relapsed/refractory AML.
- Trial name
- NCT07091006
- Testing
- VAH
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Patients are being asked to participate in this study because they will be receiving a stem cell transplant as treatment for their disease.
- Conditions
- Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- CASPALLO (NCT00710892)
- Testing
- Allodepleted T Cells
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine